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ABSTRACT

Tissue engineering is a process of developing new tissues in a host. Tissue
engineering draws upon revitalizing damaged tissues that otherwise would not heal
completely from the body’s natural response. To augment the body’s natural response to
impairment, cells can be transplanted to the afflicted area to boost the healing response.
Implementing these cells onto scaffolds and transplanting them into the body improves
the healing response dramatically. Tissue regeneration improves when a biodegradable
scaffold is used in conjunction with cells to augment the body’s healing response.
Microparticles provide a surface that can mimic the environment cells perceive in vivo,
allowing cells to proliferate and grow on the microparticle surface optimally. When
these microparticles are transplanted into the body, the accompanying cells transition
into the host tissue as the microparticles degrade. Proteins comprising the extracellular
matrix (ECM), like collagen, fibronectin, and laminin, are used to facilitate cell binding
to substrates, whether a biomaterial material ex vivo or an enzyme in vivo.
Functionalizing the surface of microparticles with ECM proteins improves the adherence
of cells which increases the area of tissue regenerated. When cells bind to ECM proteins
on a biomaterial, a cascade of signals is initiated which communicates to the cell to
spread on the surface of the biomaterial and begin the process of mitosis, leading to
proliferation. Cationic polymers have also been shown to improve cell-surface
interactions. Functionalizing particles with cationic polymers and extracellular matrix
proteins provides a surface optimized for cell attachment and spreading.
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SECTION
1. INTRODUCTION

Tissue engineering is a quickly developing field that has the potential to change the
face of medicine. Engineering tissues requires the use of both cells and non-cytotoxic
materials. These materials can be either synthetic, natural, ceramic, or metallic. Metallic
and ceramic materials are best used in joint replacement procedures, such as hip or knee
replacement, because these joints should last for at least 10 years or more. Additionally,
metallic and ceramic materials have larger Young’s moduli and thus are more resistant to
stress and strain, which is required in large joints. However, metallic and ceramic
materials are still prone to inflammation and immune response leading to implant
degradation over time. Since new tissue is not formed in these implants the body will
eventually reject the implant requiring the implant to be removed and replaced. While
metallic and ceramic biomaterials are stronger and more resilient, natural or synthetic
scaffolds show promise in permanent remedies for biological damage.

1.1 SYNTHETIC BIOMATERIALS
Synthetic biomaterials are composed of polymers with a range of properties.
Synthetic scaffolds are robust and versatile and can be used in a variety of tissue
regeneration processes. Most synthetic scaffolds are polymeric, with polyesters being
common, and can be fashioned into constructs similar to natural scaffolds, however,
synthetic materials can range from weak to strong mechanical properties, long to short
degradation times, and bioinert to biodegradable, while maintaining low to zero
cytotoxicity [1]. Synthetic scaffolds benefit from stronger mechanical properties,
resistance to dangerous biological environments, control over degradation rate, and are
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easily modifiable and tunable compared to natural biomaterials [2]. When considering
tissue regeneration, the strength of the biomaterial is of pivotal importance to support the
tissue they encompass in order to prevent plastic degradation, or irreversible degradation,
or breakage. Depending on which tissue is being regenerated will influence what material
is chosen as a scaffold. For example, the Young’s modulus of bone is 338.3 MPa [3]
whereas cartilage tissue has a Young’s modulus of 0.45 to 0.8 MPa [4]. To regenerate
either of these two tissues, the biomaterial chosen should have a Young’s modulus close
to that of the tissue. In addition, the degradation rate of the biomaterial must be chosen
such that the material degrades at a similar rate that tissue regenerates. Tissues in the
body rejuvenate at different rates and this requires that a biomimetic scaffold degrade at a
rate that matches rejuvenation of the damaged tissue. The degradation rate should match
the proliferation rate of the cells composing the damaged tissue such that a seamless
incorporation of implanted cells occurs. However, most synthetic scaffolds do not readily
associate with cells like their natural counterparts, which is a critical aspect of tissue
engineering. Synthetic scaffolds are typically hydrophobic, carrying a net negative charge
which is known to repel cells due to their net negative charge around the plasma
membrane [5]. To effectively achieve cellular attachment to synthetic scaffolds, surface
functionalization is typically required. Scaffolds are functionalized through physical
adsorption [6], bioconjugation [7], or plasma polymerization [8] with extracellular matrix
proteins [8-10] or cationic polymers [11-14]. Extracellular matrix proteins contain
specific amino acid sequences that anchorto receptor proteins on the cell membrane [15],
whereas cationic polymers utilize electrostatic interactions to associate with cellular
membranes [16]. The biomaterial most advantageous for which tissue is engineered

3

depends on the recovery rate of the tissue. Bone, cartilage, skin, muscle, and heart tissue
each have unique regeneration responses. Each of these tissues use specific signal
cascades to deliver different types of cells and growth factors at certain times in their
regeneration process. Due to the varied wound response of each tissue, a biomaterial to
regenerate these tissues must be carefully chosen. A variety of materials are available for
tissue engineering such as polycaprolactone (PCL), poly(glycolic acid) (PGA),
poly(lactic acid) (PLA), poly(methyl methacrylate) (PMMA), polystyrene, and
Poly(lactic-co-glycolic) acid (PLGA). PCL has a long degradation time and is useful for
applications where slow, continual repair or drug delivery is required. PGA is a
hydrophilic polymer that has been used for synthetic, biodegradable sutures due to its
quick degradation time. PLA is a hydrophobic polymer, owing to the methyl pendant
group off its main chain, and has been used for stents for blood vessel stenosis [17].
PMMA is a bioinert material with powerful mechanical strength and has been used as
bone cement. Polystyrene particles have been used to study the effect of different shapes
of micro and nanoparticles in relation to their uptake in cancer cells [18]. PLGA is a
versatile biomaterial which is FDA approved and has been used in drug delivery, and
tissue regeneration [12, 19]. PLGA degrades through hydrolysis into lactic and glycolic
acid. Lactic acid is naturally produced during anaerobic cellular respiration and is
excreted as waste. Glycolic acid is an extremely water-soluble molecule; thus, it is easily
removed from the body as waste in urine [20]. PLGA is versatile in that it can be
fabricated into fibers [21], constructs of varying dimensions by sintering [22], disk [18],
rods [23], or particles [24]. PLGA is a prime contender for tissue engineering
applications because of its degradation rate, mechanical strength, and ease of
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functionalization. PLGA degradation rate can be controlled by varying the ratio of
glycolic acid to lactic acid in the copolymer. When composed of a 50/50 mix of the two
comprising polymers, PLGA experiences its quickest degradation rate; undergoing
complete degradation within 4 weeks in vivo. By increasing the molar ratio of lactic acid
in PLGA, the degradation rate can increase to 7 months, whereas increasing the glycolic
acid ratio increases degradation rate to at most 5 months. Therefore, PLGA can be used
in a wide variety of tissue regeneration applications. Additionally, PLGA naturally
consists of carboxyl groups due to the presence of glycolic acid. These carboxyl groups
allow PLGA to be modified with proteins through amine coupling in bioconjugation
processes. Modifying the surface of PLGA with proteins increases the ability for cells to
associate with the biomaterial enabling augmented tissue regeneration. Using
biomaterials for tissue regeneration is important because severely damaged tissues will
not undergo complete repair like broken bones in elderly patients, or severe burns.
However, the infusion of transportable microparticle devices for cell delivery into
damaged tissues offers a new paradigm for tissue regeneration.

1.2 NATURAL BIOMATERIALS
Natural scaffolds are comprised of materials naturally found in the body. These
materials typically comprise the extracellular matrix network, which anchors cells
together as tissues, as well as structural and sensing components of the plasma membrane
on cells. Proteins are a typical natural biomaterial used in tissue regeneration. Proteins are
interesting molecules because they are synthesized in a cell, from translated messenger
ribonucleic acid (mRNA), and are built in a structural hierarchy. The mRNA is translated
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by ribosomes into amino acids, which are the building blocks of protein. There are 20
common amino acids which form all proteins found in the body. These amino acids are
linked together in a chain by peptide bonds, which forms the first-degree structure of
proteins. Depending on the amino acid profile of the peptide chain, the peptide conforms
into one of two secondary structures: an alpha helix or beta sheet. The alpha helix and
beta sheet are stabilized through hydrogen bonds between successive amino acids. These
secondary structures associate with each other through hydrogen bonding as well as
disulfide bonds between cysteine residues to form a tertiary structure, which is the threedimensional representation of a protein. This tertiary structure undergoes folding and
modification to form a functional protein. Furthermore, these tertiary structures will
associate to form a quaternary structure, which is at least two tertiary proteins binding
together through disulfide bonds and hydrogen bonding.
Natural scaffolds are derived from materials occurring naturally in vivo such as,
hyaluronan [10], chitosan [25], chondroitin-6-sulfate [26], collagen [27], and many others
[28] and have been prepared as films [29], hydrogels [30], fibers [31], and particles [32].
Chitosan is an interesting biomaterial considering it is an amino polysaccharide
consisting of N-acetyl-D-Glucosamine. Chitosan is formed from the deacetylation of
chitin, a hard material used by shrimp, crabs, and other shellfish for their shells. The
deacetylation step allows for chitin to polymerize with D-glucosamine via glycosidic
bonds, forming the cationic polymer chitosan. Due to the large number of amino groups
littered on the backbone of chitosan, it has large potential as a tissue engineering material.
The amino groups will carry a positive charge at physiologic pH (7.4) which will help
associate with the negatively charged plasma membrane of cells. In addition, chitosan is
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mucoadhesive and thus can bind to mucus membranes [33]. Chitosan is especially useful
as a hydrogel [34] since it can incorporate numerous bioactive compounds through
electrostatic interactions and amide bonds. Nucleic acids, like DNA, are a promising
natural material for regenerative medicine. DNA has been formed into many shapes and
structures and is a potential nanomaterial for drug delivery, biomarkers, and shape
controlling of hydrogels [27]. However, DNA is limited in tissue engineering as it is
difficult to fabricate into large structures. Additionally, the net negative charge of DNA is
a natural repellent of the plasma membrane, limiting its ability to associate with cells.
These biomaterials show virtually no cytotoxicity and many compose the extracellular
matrix or are involved in cell anchoring, spreading, and communication [14, 35]. In this
manner, natural materials are advantageous for tissue engineering because they naturally
associate with cells and stimulate cellular proliferation. However, natural biomaterials,
especially proteins, are subject to hydrolysis and enzymatic degradation in vivo.
Additionally, natural materials suffer from limitations in synthesis. Many natural
materials must be maintained in solutions that are at or near physiologic pH, otherwise
they will degrade. Proteins are dependent on temperature to maintain proper structure,
otherwise known as their native conformation. Above 37ºC proteins degrade into their
amino acid constituents and lose their function, likewise, materials made solely out of
proteins can not withstand temperature fluctuations. Natural scaffolds also suffer from
weaker mechanical properties and quicker degradation in atypical somatic environments,
such as the acidic pH environment at wound sites, relative to synthetic biomaterials.
Thus, natural scaffolds are a useful tool for tissue regeneration, however, their capacity is
limited when used on their own.
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1.3 TISSUE ENGINEERING
In the presented study, synthetic biomaterials were coupled with materials derived
from naturally occurring proteins in the body for the attachment of endothelial cells.
Endothelial cells line the lumen of blood vessels and are defined as either vascular or
lymphatic depending on whether they are in contact with the blood or lymph,
respectively. These cells diffuse nutrients and oxygen from the blood to tissues
throughout the entire body as endothelial cells line the entire vasculature. Additionally,
they act as a mediator for immune cells to traverse the body and infiltrate wounded and
diseased tissues. Blood vessels are responsible for many functions like fluid filtration in
the kidneys, maintaining homeostasis, and delivering hormones. When a tissue, such as
skin, incurs damage, blood vessels are typically damaged as well, which is apparent when
someone bleeds. By using biomaterials to deliver endothelial cells to damaged tissues, an
increased response to wound repair is expected. These cells participate in angiogenesis,
which is the formation of new blood vessels. Considering that blood vessels are
responsible for delivering oxygen and removing wastes from tissues, delivering these
cells using biomaterials is important in regenerating tissue. For example, when someone
suffers from a heart attack there is a chance that acute myocardial infarction can develop.
When a patient suffers from acute myocardial infarction part of the tissue in the heart dies
and is repaired by fibrosis. Fibrosis occurs when scar tissue forms to repair a wound site.
It is possible that stimulating tissue which has suffered myocardial infarction with
endothelial cells will improve wound repair and prevent scar tissue formation and
fibrosis.

8

Li et. al. used trophoblast and mesenchymal stem cells to augment repair of
myocardial infarction in a mice model [36]. The group instigated myocardial infarction,
colloquially known as a heart attack, in a mouse, then applied stem cells derived from
embryonic blastocysts. Trophoblast and mesenchymal stem cells were successfully
delivered to the heart and did reduce the area of infarction, however, only 8% of the stem
cells successfully engrafted into the tissue and proliferated. A majority of the cells did not
transplant to the target location and were flushed away by the mouse’s excretory system.
Low engraftment rates are a pivotal issue in cell-based therapies. Many regenerative
therapies suffer because cells do not efficiently adhere to the wounded tissue. These cells
have difficultly incorporating into tissues of interest because the body’s blood vessels are
constantly pushing fluids through every system in the body. Cells get flushed away
during this cycle. To alleviate excretion of cells biomaterials are being developed which
can target wounded tissues and bind cells. Using biomaterials as a mediator for tissue
regeneration improves cell engraftment in damaged tissues. Additionally, these
biomaterials can be functionalized to bind specific types of cells as well as target specific
tissues, rather than the “shotgun” approach of administering cells in a wholesale fashion.
Furthermore, the advent of microparticles facilitates ease of administration through
minimally invasive surgical procedures. Also, microparticles are versatile and can be
applied to virtually all tissues and are modular in that they can be functionalized to enable
attachment of any cell type. The present investigation elicits the potential of these
microparticles such that their surface can be functionalized through bioconjugation or
physical adsorption using either extracellular matrix derived proteins, like gelatin, or
polycationic polymers like poly-l-lysine (PLL).
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PAPER
I.

PLGA MICROPARTICLES AS VEHICLES FOR CELL TRANSPORT

ABSTRACT

Tissue engineering offers promising solutions for the future of regenerative
medicine. Current technology focuses on metallic or ceramic implants for replacement
therapy, direct application of cells to damaged tissues, or large constructs or hydrogels.
Particles offer a promising approach to tissue regeneration, however, many studies have
been limited to small particles sizes (<50 µm) which limits the extent to which cells can
attach and be modelled as a biomimetic device. Here, the efficacy of a simple flowfocusing device coupled with the single emulsion solvent diffusion technique to fabricate
poly(lactic-co-glycolic) microparticles for attachment of human umbilical vein
endothelial cells (HUVECs) is demonstrated. PLGA microparticles measured at 122 ±
40.4 µm in diameter and reached up to 156 ± 39.9 µm in coated formulations. Zeta
potential ranged from -16.7 to -35.1 mV. Coating efficiency ranged from 30.6 ± 1.51% to
76.8 ± 4.94%. Particles were assessed for cell binding potential using confocal and light
microscopy as well as flow cytometry. A mixture of cationic polymer and extracellular
matrix adsorbed on the surface of the microparticles resulted in the most cells attaching to
the surface.
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1. INTRODUCTION

Biodegradable and biocompatible materials offer an effective channel for advancing
regenerative medicine and tissue engineering. Common polymers in use are poly(lacticco-glycolic acd) (PLGA) [1-3], poly(lactic acid) (PLA) [4, 5], polycaprolactone (PCL),
and polyethylene glycol (PEG) [6] and are FDA approved for use in vivo [7]. One of the
barriers for biomaterials to overcome is cell attachment and delivery. Tissue engineering
requires delivery of cells to a target site to induce healthy regeneration and prevent
hazardous scar tissue formation. Tissues with large scar areas are prone to malfunction
and increased risk of further injury. In fact, a wound area which encompasses a large
fraction of tissue surface area can not fully repair by natural mechanisms [8], total repair
requires the use of a biomaterial to augment the regeneration response. Biodegradable
materials are chosen for their degradation rate, mechanical properties, and surface
characteristics. Their unique ability to interact with the human body without producing a
cytotoxic or immune response facilitates their use as a scaffold for culturing cells. PLGA
is a versatile biomaterial which degrades due to hydrolysis in as little as two weeks [9].
Current studies demonstrate the efficacy of PLGA as an instrument for regenerating
cardiac [10], nervous [11, 12], hepatic [13], cartilage [14], and skin tissue [15]. However,
current studies have not thoroughly investigated the capability for microparticles to
induce tissue regeneration, especially in skin tissue reconstruction. Particles are easily
distributed in vivo by minimally invasive surgical techniques, rather than open surgery
for implants and large constructs. This reduces the inherent risk to patients and provides a
safe solution to tissue repair. Certain formulations of PLGA degrade within 2-4 weeks
once implanted in vivo [16] which is ideal in the regeneration of severe wounds. The
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initial wound response in vivo where the majority of cellular repair including
vascularization and mending of the wound gap takes place within a month of the initial
wound incursion [17].
A major limitation in improving tissue regeneration and repair in the body is cellular
attachment to biomaterials. Extracellular matrix is a critical component for cell survival,
proliferation, and attachment. The extracellular matrix not only functions as an anchor for
cells to adhere to and spread on, but also acts as an information boulevard for cells to
communicate with each other through signaling molecules. Synthetic biomaterials lack
these extracellular domains that cells recognize and thus require modification for healthy
cell attachment. When an extracellular matrix is lacking in a cell’s environment,
programmed cell death, like anoikis or apoptosis, can occur. Thus, biomaterials are
functionalized with extracellular matrix proteins, such as fibronectin [18], collagen [5], or
laminin [19], or cationic polymers like chitosan [20, 21] or poly-l-lysine (PLL) [22].
Endothelial cells line blood vessel walls and provide an intricate super highway for
nutrient and gas delivery throughout the body. Thus, endothelial cells are found in most
tissues of the body including organs, muscles, and bones. Curiously, in skin only the
dermis is vascularized, whereas the epidermis receives nutrients through diffusion from
the dermis and from the environment. Endothelial cells are crucial for maintaining this
homeostasis as skin relies on dense vascular networks to deliver excesses of nutrients
such that the epidermis is properly maintained. However, in severe burns, abrasions, or
ulcers, the skin loses its ability to completely regenerate leaving the formation of a scar.
The scar tissue formed consists of extracellular matrix proteins aggregated to seal the
wound site. However, the use of biomaterials as vehicles for cellular delivery to augment

12

tissue repair response has the potential to prevent malignant bodily responses. Delivery of
endothelial cells to the wound site would increase vascularization marking an
improvement in vital nutrient delivery. Transporting cells effectively has proved
challenging since biomimetic scaffolds typically require extensive surface modification
in the form of plasma polymerization [5, 23, 24] conjugation chemistry [2,14], or
physical adsorption [11], while the literature seldom mentions endothelial cell attachment
to microparticles.
Herein is described a simple but effective method for endothelial cell attachment.
PLGA microparticles were fabricated using a modified version of the single emulsion
solvent-evaporation method utilizing a proprietary flow-focusing device. Additionally,
particles were surface functionalized for cellular attachment by physical adsorption of
PLL, gelatin, or a combination of both. Finally, particles were assessed for cell
attachment and potential.
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2. MATERIALS & METHODS
2.1 MICROPARTICLE SYNTHESIS
The solvent diffusion method was used with a simple flow-focusing apparatus to
synthesize polymer microparticles. Firstly, an organic solution was formulated by
dissolving 300 mg of Poly(D,L-lactide-co-glycolide) (PLGA; Acros Organics, ~19 kDa)
in 4.5 ml of ethyl acetate (Fisher Scientific). An aqueous solution of 1 % (w/v) polyvinyl
alcohol (PVA; Sigma-Aldrich, 30-70 kDa) was formed by dissolving PVA in reverse
osmosis (RO) water. A flow-focusing apparatus was assembled with 5 and 10 ml
syringes, a two-syringe pump (kdScientific, KDS-200), plastic tubing, a Pasteur pipette,
and a stir plate. The 5 and 10 ml syringes were completely filled with the PLGA and 1%
PVA solutions, respectively; these represent the organic and the aqueous carrier streams
of the flow-focusing apparatus.
By using an equal drive block velocity on both syringes, the two streams were
injected into the Pasteur pipette at a 7:10 flow rate differential. With careful adjustments,
gently forcing the organic stream tubing into the pipette neck produced regularly-sized
organic droplets surrounded by the aqueous carrier stream in the pipette capillary. The
Pasteur pipette was positioned vertically above 100 ml of the 1 % PVA solution (stirring
at approximately 250 rpm) such that the pipette tip was just submerged near the center of
the solution’s vortex whorl. For 10 minutes of injection, the organic droplets were
dispersed into the continuous aqueous phase. The Pasteur pipette was then removed, and
the emulsion was stirred for an additional 15 minutes. The mixture was left undisturbed
overnight (> 18 hours) to allow for evaporation of residual ethyl acetate at room
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temperature. PVA was removed by centrifugation at 7,000 rcf, followed by five washes
with RO water. Microparticles were then lyophilized, weighed, and stored at 4C.

2.2 MICROPARTICLE CHARACTERIZATION
The size and surface topography of PLGA microparticles were analyzed with SEM at
1-10 kV (Hitachi S-4700) and stereo microscopy (Hirox KH-8700). Particle size and
shape were also visualized with bright field microscopy (Nikon Eclipse E400). The
microparticle surface charge was measured in water and phosphate buffer saline (PBS;
Fisher Scientific) with dynamic light scattering (DLS; Malvern NanoSeries Zetasizer
ZS90). DLS measurements were performed at 25C in disposable capillary cells
(Malvern) using the backscattering detection at 90. The zeta potential was measured for
20 successive runs. Data was analyzed using means and standard deviations of three
measurements.

2.3 SURFACE COATING OF MICROPARTICLES
Poly-l-lysine (Sigma, PLL, MW ~150,000-300,000 Da) and gelatin from bovine
(Sigma, bloom ~ 225-300) were physically adsorbed onto the surface of PLGA
microparticles to increase cell-particle interactions. Briefly, 35 mg of microparticles was
weighed and added to three centrifuge tubes for PLGA-Gel (PG), PLGA-PLL (P2), and
PLGA-PLL/Gel (P2G) particles. All tubes were coated in Sigmacote® (Sigma) to
minimize product loss. For PG particle formulations, 75 μl of a 0.32% w/v solution of
gelatin in RO H2O was added, for a total of 240 μg of gelatin. P2 formulations received
240 μl of a 0.1% w/v PLL solution, P2G particles 45 and 96 μl of gelatin and PLL stock,
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respectively, for a total of 240 μg of protein at a ratio of 40/60 PLL/Gel. Samples were
incubated at 37°C and rotated at 20 rpm for 4 hours. Particles were then centrifuged at
4,696g for 20 minutes and washed 3 times with RO H2O. Microparticles were then
lyophilized, weighed, and stored at 4°C.

2.4 SURFACE COATING QUANTIFICATION
To effectively determine the amount of PLL and gelatin adsorbed on the surface of
PLGA microparticles, nuclear magnetic resonance (NMR) analysis was employed.
During the washing of coated particles, the supernatant was collected for NMR analysis.
The supernatant was frozen and lyophilized until constant weight was achieved. This
product was then diluted in 700 μl of deuterium oxide (D2O) and analyzed using 1H
NMR (INOVA 400 MHz FT/NMR, Varian, Inc.). Spectral data was collected and
analyzed for the integral area under characteristic peaks for PLL and gelatin. The area
under the characteristic peaks was used to calculate total protein content in the
supernatant samples using a standard curve. Percent adsorption efficiency was then
determined using the following equation:

%𝐴𝐸 =

𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − 𝑆𝑎𝑚𝑝𝑙𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
∗ 100%
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛

(1)

2.5 CELL ATTACHMENT, PROLIFERATION, & QUANTIFICATION
Human Umbilical Vein Endothelial Cells (HUVEC, Lonza) were maintained in
Endothelial Growth Medium (PromoCell), supplemented with 2% v/v fetal calf serum
(FCS), 1 μg/ml hydrocortisone, 0.1 ng/ml human epidermal growth factor, 1 ng/ml basic
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fibroblast growth factor, 90 μg/ml heparin, and 1% penicillin-streptomycin in an
incubator at 37°C and 5% CO2. Medium was changed regularly every 2-3 days and cells
were subcultured at ~80% confluence according to manufacturer’s protocol. Cells were
collected via trypsinization, centrifuged at 200 g for 5 min and resuspended in fresh
media at the appropriate concentration for bioreactor addition. The bioreactors used in
this study were sterile 50 ml bio-reaction tubes (CELLTREAT, Pepperell, MA) with a
hydrophobic membrane cap facilitating the diffusion oxygen and CO2 into the
bioreactors. Bioreactors were not tissue culture treated such that cells would not attach to
the surface of the tube. Cells were seeded at a constant cell density of 20,000 cell/cm2 in
bioreactor samples as well as T-75 control flasks. Microparticles were sterilized by UV
for 15 minutes before commencing cell attachment. The cell-particle mixture was stirred
continuously at 50 rpm in an incubator at 37°C and 5% CO2 for 24h, thereafter cells were
no longer subject to stirring. At 4, 8, and 24h after initial seeding, particles were aspirated
from their bioreactors and investigated for cell viability, proliferation, and cell loading
capacity. Additionally, control flasks were trypsinized, collected, and subject to the same
analysis. Cell viability was determined by staining cells with calcein-AM (CAM) and
bright field microscopy. Cell proliferation was determined by performing flow cytometry
analysis in conjunction with a live cell assay using CAM staining. Briefly, 200 μl of each
bioreactor sample and control was aspirated and collected in 0.6 ml microcentrifuge
tubes. CAM was added to each sample at a concentration of 2 μM, and incubated at room
temperature for 30 minutes. Subsequently, samples were analyzed using a flow cytometer
(BD Accuri C6 Plus, BD Biosciences). Gates were determined for each control (particles,
cells, media) and data was analyzed to determine cell concentration, density, and
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attachment efficiency. Further, cells-particle samples were fixed with 4%
paraformaldehyde and analyzed by SEM. Additionally, fixed samples were perforated
with 0.1% v/v Triton X-100 in PBS and stained with 30 µl of 5 mg/ml 4’,6-diamidino-2phenylindole (DAPI) for 5 minutes as well as 205 µl of 6.6 µM tetramethylrhodamine
isothiocyanate (TRITC, rhodamine phalloidin) for 30 minutes. Samples were washed
with PBS, mounted, and dried under vacuum desiccation and subsequently visualized
using confocal laser microscopy (TCS SP8, Leica Camera AG).
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3. RESULTS & DISCUSSION

3.1 PARTICLE CHARACTERIZATION
Microparticles in this study were designed to reach a peak size in which the particles
would reach a maximum surface area while not sacrificing cell binding ability. Initially,
10% w/v PVA was used as the concentration for particle formulation, however, these
microparticles never surpassed 40 μm in diameter. We attempted to alleviate this issue by
decreasing the PVA concentration from 10% w/v to 1% w/v, which is known to increase
particle size [3], as well as reducing the stirring time of particles after pumping the carrier
and organic streams through the flow-focusing device. This resulted in a particle size
increase of bare PLGA particles to 122 ± 40.4 μm (Table 1). The bare particles were
spherical in shape and displayed a relatively uniform size for larger particles (Figure 1).
SEM images indicate that the bare particles are indeed spherical and slightly porous,
which is most likely due to evaporation of ethyl acetate prior to washing and evaporation
of entrapped water during lyophilization. Zeta potential measurement of the bare PLGA
particles was -26.9 mV and -16.7 mV in H2O and PBS, respectively. These values are
lower in absolute value than those typically reported for PLGA [25, 26] which is most
likely due to the extreme size of the microparticles which decreases the surface charge
density. Modifying the surface of polymeric particles, especially with extracellular
matrix constituents or polycationic materials, is known to induce many alterations in the
particles’ properties [2, 14, 19]. During the coating procedure, particles are coated in a
37°C environment in a solution consisting of PBS. These conditions help facilitate
coating through physical adsorption by reducing the strength of the polymer’s bonds, by
bathing the particle in conditions closer to its glass transition temperature. This causes the
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particle to associate with the proteins in solution by increasing the frequency at which
end groups experience van der Waals interactions which induces adhesion of the protein
molecule to the particle surface [27]. Additionally, this elevated temperature catalyzes
degradation of PLGA particles due to hydrolysis [9]. As of a result of these phenomena,
coated particles developed interesting architecture (Figure 1). The brightfield images of
each coated particle, whether gelatin, PLL, or a combination of the two was used as
coating, display a central section surrounded by a lighter area. This result suggests a few
things about these particles. One, that the particles are coated in a relatively thin protein
coating, causing an expansion in particle size (Table 1). Secondly, the particles most
likely have undergone some level of degradation during the 1.5 hr incubation period at
elevated temperature. Comparing the brightfield images (column A, Figure 1) of the
PLGA particles compared to PG, P2, and P2G, the PLGA particles are black and devoid
of light passing through whereas the coated particles are substantially lighter indicating
that more light passing through the aperture and a less dense particle. Additionally,
coated particles are much less regular in shape when compared to the bare PLGA
particles, indicating that protein coating induces shape change in the particles. Comparing
the SEM images in columns B, C, and D, the bare PLGA particles are more regular in
shape and lack the degree of particle debris/degradation in the coated formulations. Most
notable from column B, the act of rotating particles in an elevated temperature
environment seems to induce particle deformation and breaking which is not seen in bare
PLGA particles which are not subject to such forces. PLL coated PLGA particles
especially experience this sort of degradation because much of the particles have
fragmented into irregularly shaped chunks.
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Table 1: Particle Characteristics. Average particle diameter is the mean value of 50 or
more particles.
Particle Type

Average Particle
Diameter

No. of Particles/g

PLGA

122 ± 40.4 μm

1.05•10 ± 0.193•10

PLGA-Gel

136 ± 42.1 μm

0.760•10 ± 0.122•10

PLGA-PLL

156 ± 39.9 μm

0.503•10 ± 0.133•10

PLGA-PLL/Gel

140 ± 47.0 μm

0.696•10 ± 0.087•10

A

6

B

No. of
Particles/ml
6

3,700

6

6

3,000

6

6

2,200

6

6

2,800

C

D

PLGA

PG

P2

P2G

Figure 1: Microscope Images of Particles. (A) Light microscopic images of PLGA
microparticles with and without adsorbed coating (10x); SEM images of each particle
formulation at (B) 150x, (C) 500x, (D) 1,500x magnifications; (B, C) depict particle
morphology, indicating porous structures and a rough surface for protein coated particles;
(D) Single particle surface image comparing the roughness and porosity of each particle
formulation. Coated particle (PG, P2, P2G) surfaces are rough and irregular indicating a
coating has formed on the particle whereas PLGA particles are homogeneous and porous
indicating a lack of such coating. PG = PLGA-Gel; P2 = PLGA-PLL; P2G = PLGAPLL/Gel
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Finally, it is quite apparent that physical adsorption of proteins to microparticles
increases the surface roughness of the particles (column D). Particles coated with gelatin
and PLL experienced a substantial size increase (Table 1). Size measurement was a
crucial part of our investigation because cells were seeded at a constant density based on
surface area. Due to the diameter increasing by the protein coating, coated particles had a
larger surface area per particle. Thus, less of these particles were necessary to achieve the
control area used in cell experiments.
One of the notable changes when modifying microparticle surfaces is the zeta
potential measurement. Zeta potential describes the electric potential between a particle
surface and the suspension medium at the plane in which counter-ions to the particle
surface do not move with the particle [28, 29]. All particles were measured for zeta
potential in H2O and PBS. PBS was used to mimic in vivo conditions such as pH and ion
concentration. For all coated particles, zeta potential increased in absolute value, whether
in H2O or PBS, compared to bare PLGA particles (Figure 2). Zeta potential values were 27.9, -35.1, and -26.1 mV in H2O, and -23.4, -25.1, and -19.9 mV in PBS for PG, P2,
and P2G respectively. Interestingly, particles coated with PLL (P2) experienced the most
negative zeta potential value, which is unusual for PLL coated materials [11, 30]. The
zeta potential of gelatin coated particles was negative and higher than that measured for
bare PLGA as well. When placed in PBS, all particles had a decrease in zeta potential,
relative to when H2O is the suspension medium. This suggests that coating with proteins
like gelatin and amino acid polymers like PLL increases the stability of PLGA
microparticles, since a higher absolute value of zeta potential prevents particle
aggregation and flocculation [31]. The PLL loading of P2 particles was 6.86 µg/mg
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particles which is sufficiently low, given the extreme size of the particles, to prevent a
positive zeta potential. Thus, the loading of coating solution on PLL conjugated particles
is too low to completely cover the surface of the microparticles.

10

Apparent Zeta Potential (mV)

0
-10
-20
-30
-40
-50
-60

PLGA
H2O

PG

P2

P2G
PBS

Figure 2: Zeta Potential
Zeta potential for each particle formulation measured by dynamic light scattering (DLS)
and electrophoretic mobility. Each sample was measured in both RO H2O and PBS, blue
and grey bars, respectively. Error bars are mean ± standard deviation.
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3.2 SURFACE MODIFICATION
Particles fabricated from PLGA typically repel cells because of the hydro
hydrophobic nature of the polymer [14, 32, 33], unless the particle surface is modified.
To improve interactions between particles and cells, PLGA microparticles were coated in
PLL, gelatin, or a mixture of both, and analyzed quantitatively using nuclear magnetic
resonance (Table 2). Particles coated with gelatin, PG and P2G, experienced the highest
total conjugation efficiency at 62.9% ± 4.53% and 76.8% ± 4.94%, respectively, while a
conjugation efficiency of 30.6% ± 4.94% was observed for PLL coated particles. Given
the conjugation efficiency, P2G particles, which are a 40/60 mix of PLL/Gelatin, had the
highest coating density and therefore the most protein/poly-amino acid adsorbed. Thus,
there must exist a synergistic adsorption effect for PLL and gelatin on the surface of
PLGA microparticles which may translate to mixtures of proteins other than gelatin.

Table 2: Adsorption Capacity of Microparticles. Particles were loaded with a uniform
ratio of total protein mass to particle mass. P2G particles were prepared using a 60/40
mixture of gelatin/PLL. Conjugation efficiency and protein density was determined using
a standard curve prepared by NMR analysis. Protein density was calculated using the
surface area per mg of bare PLGA particles.
Initial MassLoading
(μg/mg Particles)

Total
Conjugation
Efficiency

Coating Density
(µg/cm2
Particle)

Adsorbed Coating
(µg/mg particles)

PG

6.86

62.9 ± 4.53%

9.79 ± 0.72

4.19 ± 0.310

P2

6.86

30.6 ± 1.51%

4.85 ± 0.194

2.08 ± 0.083

P2G

6.86

76.8 ± 4.94%

12.0 ± 0.79

5.13 ± 0.338

Particle
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3.3 CELL ATTACHMENT, PROLIFERATION, AND QUANTIFICATION
Particles were prepared using a basis surface area of 14 cm2 and cells were seeded
at a constant cell density of 35,000 cells/cm2 for both controls and particle samples.
Microscope images and flow cytometer measurements were taken at 0, 4 (Figure 3) and
8h (Figure A.1).

Control

PLGA

PG

P2

P2G

0h

4h

Figure 3: Microscopic Characterization of Cell-laden Particles.
Fluorescent microscope images of cell-particle samples. Top row is images taken at 0h,
or initial seeding, and bottom row is images taken at 4h post-seeding. Control images
were taken in a 96 well plate, particle samples were aspirated from bioreactor tubes,
stained with 2µM CAM, and plated on microscope slides.

Images taken at 0h show viable cells fluorescing green, however, most cells are
rounded and not clearly associated with particles, indicating attachment has not occurred.
At 4h, cells attach to PLGA particles, but are clustered in aggregates indicating a higher
affinity for cell-cell interactions rather than cell-particle binding. However, coated
particle samples do not display clear cell aggregation. Cells attached strongly to P2 and
P2G particles at four hours whereas PLGA and PG particles show some cell attachment
mixed with cell aggregates, with many cells in the fluid surrounding the particles. This
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suggests that while cells are present in the samples they do not bind as well to bare PLGA
and gelatin coated PLGA particles.
Cell attachment to particles was further confirmed using confocal laser microscopy
coupled with actin and nucleic staining (Figure 4). Cells were not observed in PLGA
particles, however, PLGA particles physically adsorbed the phalloidin stain giving off a
bright red fluorescence. Surface modified particles, PG, P2, and P2G, all were positive
for cell attachment as confirmed by phalloidin and DAPI fluorescence on the surface of
particles.

PLGA

PG

P2

P2G

Figure 4: Confocal Laser Microscopy. Microscopic images taken at 20x on a Leica TCS
SP8 confocal laser microscope. (A) PLGA and PG particles, top row: DsRed and DAPI
channels showing actin and nucleic staining; bottom row: light microscopic image of the
same frame. PLGA particles showed no cells in the sample, but adsorbed phalloidin dye.
(B) P2 and P2G particles, top row: DsRed and DAPI channels; bottow row: DsRed,
DAPI, and light channels of particles.

All surface modified particles displayed extensive cell attachment on the edges of the
particle. The extent of cell spreading and attachment on surface modified particles is
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confirmed through fluorescent microscopy (Figure 5). Images represent threedimensional renderings of z-stack compiled images. Cells were stained with calcein AM
(CAM). The bottom row resembles a “heat map” of the fluorescent channel depicting the
elevation of cells within the 3D rendering confirming that cells have attached and spread
on the surface of the particles on the z-axis, or vertical direction.

P2

P2G

Figure 5: Characterization of Cells on Microparticles.
3D rendering of P2 and P2G samples. From top: light microscopy 3D rendering,
fluorescent channel 3D rendering, combined 3D rendering, fluorescent channel rendering
with elevation gradient. Cells are shown as spreading along the edge of particles on the zaxis confirming that cells have attached and begun to spread.
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Cell-particle mixtures were analyzed using flow cytometry to quantify the extent of
cell attachment to particles (Figure 6). SSC vs FSC plots resemble the shape and size of
the particles and cells giving an indication to the difference in diameter as well as
granularity of the samples. The FSC value indicates how much of the laser passes around
the sample while the SSC value indicates how much of the laser beam is reflected off
organelles and particulates in the cell and the matrix composing the core of the particles.
Dot plots from flow cytometer are colored green for HUVECs and purple for particles
(Figure 6a). PLGA, PG, and P2 particles all have a higher SSC value than cells, however,
P2G samples are overlapped with HUVECs in the sample. This indicates that cells are
strongly bound to P2G particles. The larger SSC value means that the particles reflect
more laser than the cells suggesting that particles have a solid core whereas HUVECs
have more empty space in their interior. Considering that cells, whether eukaryotic or
prokaryotic, are composed of cytoplasm – a gel-like substance – and polymer
microparticles are composed of a tight network of polymeric chains, it makes sense that
SSC values are higher for microparticles as more of the laser should pass through the
cell’s translucent cytoplasm.
Flow cytometry data was further analyzed to assess the proliferative capacity of
HUVECs bound to microparticles (Figure 6b, c). Cell populations were separated from
particles using gates as shown in panel A of Figure 4. The data was correlated for change
in cell density, expressed as cell/cm2, over 8 hours. All samples were initially seeded at
20,000 cells/cm2 at 0h. Notably, P2G particles realized the largest increase in cell density
at 4 hours, whereas PLGA and P2 decreased slightly and control and PG particles
experienced a slight increase. At 8 hours, only PG particles increased while all other
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particles formulations experienced a significant drop in cell density and control samples
were virtually constant.

Figure 6: Cell Proliferation and Quantification.
(A) Flow Cytometry Analysis. Qualitative flow cytometry data for cells mixed with
particles at 4h. Dot plots are color labelled as purple = particles; green = cells; M3 =
Percentage of samples that are not cells SSC vs FSC graphs depict granularity, or surface
roughness, compared to size of the sample. Particles consistently report a higher degree
of granularity as well as a bigger size. FITC Count data shows number of events which
report a certain fluorescence value – cells stained with CAM report higher values while
particles report low values. However, some overlap is observed, especially in PG and
P2G which indicates cells and particles are closely associated. SSC vs FITC data aids in
determining the extent at which particles and cells are associated. (B) Cell density over
time; (C) Relative cell density compared to control at each time point. Cell density
estimation determined from flow cytometer data.
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Figure 6: Cell Proliferation and Quantification.
(A) Flow Cytometry Analysis. Qualitative flow cytometry data for cells mixed with
particles at 4h. Dot plots are color labelled as purple = particles; green = cells; M3 =
Percentage of samples that are not cells SSC vs FSC graphs depict granularity, or surface
roughness, compared to size of the sample. Particles consistently report more granularity
as well as a bigger size. FITC Count data shows number of events which report a certain
fluorescence value – cells stained with CAM report higher values while particles report
low values. However, some overlap is observed, especially in PG and P2G which
indicates cells and particles are closely associated. SSC vs FITC data aids in determining
the extent at which particles and cells are associated. (B) Cell density over time; (C)
Relative cell density compared to control at each time point. Cell density estimation
determined from flow cytometer data.

3.4 DISCUSSION
Endothelial cells are integral to maintaining homeostasis and repairing severely
damaged tissues. They are responsible for lining blood vessels which deliver nutrients
and oxygen, both critical components of cellular health and function – especially in tissue
repair processes – as well as transport waste to the excretory system. Endothelial cells act
as a barrier between the lumen of blood vessels, where erythrocytes are located, to the
surrounding tissues by mediating the passage of white blood cells and other materials.
Due to their extensive presence in the body – endothelial cells are found throughout the
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entire circulatory system – endothelial cells have been investigated for their potential in
tissue engineering [34]. However, much of the literature has not focused on endothelial
cell delivery in tissue engineering, especially when using microparticles as a scaffold.
Microparticles offer a unique solution for the regeneration of tissues as they are easily
transportable and applied to virtually any tissue. Delivering cells via microparticles will
provide a versatile vehicle for augmenting the regeneration of tissues. Additionally,
modelling the microparticle system with HUVECs will produce a universal system for
attachment of most any cell line.
To investigate the capability of PLGA microparticles as a cell delivery vehicle of
HUVECs, particles were fabricated at a size of more than 100 µm and coated with PLL, a
cationic polymer, gelatin, a remnant of the extracellular matrix protein collagen, or a
combination of both. HUVECs were cultured with microparticles in non-treated
bioreactors for a facile and portable approach to attaching cells to a scaffold.
Interestingly, a combination of both PLL and gelatin yielded the most cell attachment to
particles, compared to bare and separately coated particles. Cationic polymers [35], like
PLL, are known to induce cell association with coated surfaces through cationic
interactions [36]. The plasma membrane surrounding cells is typically negatively
charged, while PLL is positively charged due to the ε-ammonium group on the lysine side
chain [37]. The cationic nature of PLL attracts cells at the plasma membrane viz
electrostatic forces [38], the extent of which is pH dependent [39, 40]. Thus, coating the
surface of biomaterials with PLL causes more cells to attach and proliferate [8]. After
attachment, cells typically spread on a surface and use special protein domains to anchor
themselves. However, PLL only participates in non-specific cationic adherence of cells
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[38] whereas other molecules bind cells through integrins [41, 42]. Integrins are a class of
transmembrane proteins that bind cells using cell-recognition motifs [43]. The motifs are
comprised of specific amino acid sequences like RGD [44] in fibronectin and YIGSR in
laminin [12, 46]. When integrins bind to these motifs the cell undergoes phenotypic
changes that cause anchoring and spreading on the surface. Gelatin is believed it act on
these integrin receptors as it is a derivative of collagen, an extracellular matrix protein
which anchors cells together, however, since gelatin is in a degraded form it is not as
effective and most likely has a lower concentration of integrin binding sequences. Quirk
et al. demonstrated the effect of differing concentrations of PLL conjugated to GRGDS, a
cell-recognition motif, on the extent of cell spreading using poly-lactic acid films.
Conjugating PLL to GRGDS resulted in improved spreading of cells and was comparable
to cells grown in tissue culture plates [22]. Plasma polymerization is another technique to
functionalize the surface of scaffolds for cell attachment [5, 23, 24, 47, 48]. Plasma
polymerization requires special machinery to apply a plasma gas coating to the scaffold,
which increases fabrication cost. Allyl amine is a typical compound for plasma surface
treatment of bioactive scaffolds to increase cell binding. Bible et al. demonstrated that
plasma deposition of allyl amine on the surface of PLGA particles improved cell
attachment to microparticles compared to a coating of only fibronectin or PLL [24].
However, this process requires a plasma reactor capable of gasifying a compound and
subsequently depositing it on the surface of a scaffold, which typically requires a
propriety device developed in situ.
Interestingly, PG particles only coated with gelatin did not bind cells well compared
to other particle formulations (Figure 3). Considering gelatin is a derivative of collagen,
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there should be some remnants of integrin binding domains in its amino acid
configuration. However, PG particles had a negative zeta potential (Figure 2), thus
indicating that the surface of these particles carries a negative charge. The plasma
membrane of cells also carries a negative charge, and consequently should repel the
surface of the PG particles. P2G particles, which are coated in both PLL and gelatin,
attached cells very well, most likely due to the cationic charge of PLL attracting cells and
the amino acid sequencing of gelatin enabling anchoring and spreading of cells once they
are in proximity to the particle surface. P2 particles, coated only with PLL, also saw
distinct cell association with the particle surface, however, PLL is known to be cytotoxic
[22, 37, 49]. In a parallel investigation, we studied the ability for PLL to attach MDAMB-231 breast cancer cells over 7 days (Figure A.2). These cancer cells lost viability
after 3 days in culture in PLL only coated particles, suggesting that the use of only PLL is
not suitable for cellular attachment on scaffolds meant for tissue engineering.
Microparticles can fabricated as spheres, disks, and rods [50]. In this investigation,
only spheres were analyzed for cell binding potential, however, rods have the advantage
of maintaining the same surface area as a sphere but having a more intense curvature.
Cells like to associate with surfaces that have intense curvature as this aids in spreading
as well as mimics the environment present in the body. Additionally, only HUVECs were
investigated for binding potential. Each cell line will have unique results when assessed
for binding potential to PLGA particles. Each tissue in the human body has its own
spectrum of cells each with different concentrations of integrins as well as varying
composition of these integrin proteins which effect their binding potential to bioactive
scaffolds. To account for these variations, particles can be modified with different
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extracellular matrix constituents or various cationic polymers to optimize attachment of
each cell type. PLGA particles can be copolymerized with other functional polymers such
as polyethylene glycol (PEG) [6, 32, 51] or polyethylene imine (PEI) [35] to aid in cell
association for delivery to tissues in vivo.
Further analysis is necessary to assess the potential of these microparticles cultured
with cells to regenerate tissue. In vivo or ex vivo studies should be conducted to assess
therapeutic potential of PLGA microparticles to remediate blood vessel damage as well
as induce vascularization and angiogenesis in ischemic tissues. Additionally, particles
should be fabricated as different shapes, such as rods and disks, to assess the optimum
shape for cell attachment. Other cell lines should be investigated and compared
quantitatively to determine the extent at which these particles can bind a range of cell
lines as well as gain insight into the binding domains across various cells. Lastly,
modifying the microparticle surface with various extracellular matrix proteins and
cationic polymers and assessing their binding affinities for cells, especially HUVECs,
would aid in optimizing particle formulation for maximum tissue recovery.
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4. CONCLUSION

In summary, PLGA microparticles functionalized with PLL and gelatin successfully
attached HUVEC cells, maintained cell viability, and enabled proliferation. This proves
that a simple fabrication method (Figure A.3) of microparticles coupled with facile
physical adsorption is capable of effectively binding cells for therapeutic use as well as
manufacturing large particles with sizable control. This study demonstrates that HUVEC
cells can be bound to microparticles without the use of complicated machinery, like
plasma polymerization, and surface modification requiring expensive materials, such as
purified and sterilized fibronectin or laminin. These results can be further illustrated by
applying these microparticles cultured with HUVEC cells to mice models and assessing
their potential for therapeutic recovery of ischemic tissues.
In addition to physical adsorption for protein coating, chemical conjugation was
investigated as a method to modify particles with protein, like gelatin. The bicinchoninic
acid (BCA) assay is a quick and versatile tool for quantifying protein, like fibronectin,
collagen, or gelatin, in a sample. This quantification is important data because accurate
analysis of total protein adsorbed or chemically bound to a particle provides an
interpretation into how cells respond to certain concentrations of protein. Too much or
too little adsorbed protein can drastically change cell phenotype leading to unhealthy
cells. Additionally, theoretical modelling and simulation of cell signaling mechanisms
requires precise and accurate data to be valid. Thus, paper II describes a method for
correcting N-hydroxysuccinimide (NHS) in the BCA assay.
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II.

CORRECTION IN BICINCHONINIC ACID (BCA) ABSORBANCE ASSAY
TO ANALYZE PROTEIN CONCENTRATION
ABSTRACT
Conducting the bicinchoninic acid (BCA) assay directly after a coupling reaction

using (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) (EDC) and Nhydroxysuccinimide (NHS) chemistry produces significant errors. Here we present a
correction for the quantification of gelatin in the supernatant (SN) following gelatin
conjugation to polymer microparticles using EDC and NHS chemistry. Following the
conjugation reaction, supernatants (SNs) from the gelatin-microparticle formation
reaction are treated with BCA assay reagents and quantified for the percentage of
unbound gelatin in the solution. NHS was found to interfere with the BCA assay reagents
and is dependent on incubation time. It is found that the large concentration (500 g/ml)
of NHS in the conjugation reaction interferes with the sensitivity of gelatin present in
SNs. The interference from NHS requires a careful analysis to distinguish the BCA
background absorbance from the sample absorbance. Using an NHS control solution can
correct NHS interference and thus decrease the expensive iterations in gelatin
quantification and enable accurate analysis of gelatin content. The accuracy of gelatin
quantification is further improved by reducing the BCA assay incubation time to
approximately 20 min, compared to the recommended 30 min. This re-assessment of
BCA assay is important to avoid misestimating biases in bioconjugation processes.
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1. INTRODUCTION

Bioconjugation is a driving force behind discoveries in life sciences, through the
development of new therapeutics, drug targets, and diagnostics [1-4]. One significant
impact of bioconjugation chemistry is in the quantification of total protein concentration
that serves as a key variable for process development and quality control. The total
protein release in the sample supernatant gives an estimate of unbound or secreted
proteins during a bioconjugation process. Total protein quantification calls for an
accurate, sensitive, robust and cost-efficient method. Despite substantial improvements in
commonly used bioassays, quantitative measurements of bioconjugation still face
difficulties from unexpected interferences [5-8]. For example, carbodiimide
bioconjugations using 1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide (EDC) and Nhydroxysuccinimide (NHS) are often used for water-soluble protein bioconjugates with
polymeric backbone [9-12]. However, little attention has focused on identifying the
quantity of protein being conjugated to the surface of microparticles while unreacted
reagents such as EDC and NHS may cause interference during the quantification assay
[13-15]. The bicinchoninic acid (BCA) assay is a cost-effective and is highly selective
method for determining protein concentrations, which significantly reduces the effect of
interfering substances compared to the Lowry or Biuret protein assays [16].
Our findings suggest that when measuring a protein-based polymer material, such as
gelatin, both the NHS concentration and incubation time in BCA assay must be reduced
from the standard protocol procedure in order to minimize the effect of NHS on the
absorbance measurement.
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2. MATERIAL & METHODS

2.1 PREPARATION OF GELATIN SUPERNATANT SAMPLES
Gelatin SN Samples used for BCA analysis were prepared from an EDC/NHS
conjugation procedure [17]. EDC/NHS conjugation was used because it is a simple and
effective method to bind a protein to a substrate. The reaction simply reacts a carboxylic
acid (-COOH) group to an amine group (-NH2) forming an amide bond. Briefly, gelatin
from bovine (Sigma-Aldrich) was conjugated to the surface of PLGA and PLGA-PEG
microparticles by coupling primary amines of gelatin with carboxyl groups of PLGA to
form amide bonds (NHS and Sulfo-NHS Instructions, Thermo Scientific). Particles were
suspended at 10 mg/ml in an aqueous activation buffer: 0.1 M 2(morpholino)ethanesulfonic acid (MES; Sigma-Aldrich) and 0.5 M NaCl (Fisher
Scientific) with an adjusted pH of 6.0. Activation of carboxyl groups on the PLGA
microparticle surface was accomplished through the successive additions of EDC
(Thermo Scientific) and NHS (Thermo Scientific) to yield an amine-reactive NHS ester.
Final concentrations of EDC and NHS in each reaction mixture were 0.333 mg/ml and
0.5 mg/ml, respectively. After increasing the mixture pH above 7.0, 200 μl of a 0.37%
(w/v) gelatin protein solution was added to the reaction mixtures resulting in 740 μg of
gelatin initially added, which was based on a 1.5:1 protein to particle surface area ratio.
The mixture was shaken (Fisherbrand™ Multi-Platform Shaker, Fisher Scientific) at 450
rpm for 2 h at room temperature. After 2 h, particles were separated by microfiltration
using a 500 l microcentrifuge filter (Amicon) capable of filtering out 100 kDa
molecules. The device was centrifuged at 14,000 g for 10 min and was used three times
for a total sample volume of 3 ml. This sample was used subsequently in the BCA Assay.
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2.2 BCA ASSAY
To determine the protein concentration in SN samples, a modified version of the BCA
Assay was used. First, gelatin protein standards were created in PBS to reflect the
conditions of SN samples as well as to model the absorbance behavior of the samples.
The unknown concentrations of SN samples were prepared in 1 and 50 times dilution.
Bovine serum albumin (BSA) of 2000 g/ml was used as a positive control. Each sample
and standard of 25 µl were added to individual wells with three replications in a 96 well
plate. A working reagent ratio of 8:1 was used such that 200 µl of BCA working reagent
was added to each well. Absorbance was read at 562 nm and 37°C in a microplate reader
(Synergy 2) at varying intervals throughout the course of the investigation. The PBS
blank was subtracted from the absorbance measurements of all individual standard and
unknown samples. A gelatin standard curve was prepared by plotting each gelatin
concentration in g/ml versus its average blank-corrected 562 measurements to
determine the gelatin concentration of unknown samples.
The absorbance kinetics of varying concentrations of NHS was investigated to
compare the kinetics trend of the SN samples to approximate the concentration of NHS in
the SN samples. Mixtures of 500, 400, 300, 200, and 100 μg/ml of NHS were prepared in
PBS. The NHS samples were prepared in a 96 well plate using the BCA Assay method
described previously and absorbance was measured every minute for 2 h at 37°C.
Additionally, gelatin standards were created with EDC and NHS concentrations the
same as that used in the conjugation reaction procedure. Data acquired from the BCA
protein assay were analyzed to determine protein concentration at each data point. The
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data were further processed to determine conjugation percentage of protein, where
conjugation percentage is defined by the following equation:

𝐶𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑖𝑜𝑛 % =

𝑇𝑜𝑡𝑎𝑙 𝐺𝑒𝑙𝑎𝑡𝑖𝑛 − 𝑆𝑁 𝐺𝑒𝑙𝑎𝑡𝑖𝑛
× 100%
𝑇𝑜𝑡𝑎𝑙 𝐺𝑒𝑙𝑎𝑡𝑖𝑛

(2)

To calculate protein concentration, all samples were blank (PBS) corrected.
Additionally, SN samples were “NHS corrected” by subtracting the NHS blank that
contained no gelatin (after subtracting the PBS only blank).

2.3 BCA ASSAY CORRECTED BY PRECIPITATION OF GELATIN
To confirm the concentration of gelatin in supernatant samples, a portion of the
supernatant was treated with the Compat-Able Protein Assay kit and subsequently
analyzed with the BCA Assay. Briefly, 50 μl of each supernatant sample were transferred
into a 1.7 ml microcentrifuge tube. Then 500 μl of Compat-Able Protein Reagent 1 was
added and the solution stood undisturbed for 5 min. Next 500 μl of Compat-Able Protein
Reagent 2 was added and the solution was centrifuged at 10,000 g for 10 min. The
resultant supernatant was aspirated and discarded, and the protein pellet was resuspended
in 50 μl of PBS by vortexing and sonication. Additionally, standards containing a known
concentration of gelatin and standards with gelatin and a fixed NHS concentration were
prepared and treated as described above. All samples, after pellet resuspension, were
analyzed using the standard BCA assay protocol.

45

2.4 STATISTICAL ANALYSIS
Statistical analysis was performed using the Student’s t-test by calculating mean and
standard deviation with at least three independent experiments. Results were considered
significant for p values of < 0.05.
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3. RESULTS & DISCUSSION

3.1 NHS CONCENTRATION AFFECTS BCA-BASED GELATIN
QUANTIFICATION
To our knowledge, up to now no statistically significant data has been provided in the
literature indicating how protein mixed with NHS responds to the BCA working reagent
over time. To determine an appropriate NHS concentration and incubation period for
measuring the unknown gelatin concentration, a kinetics test was conducted on a variety
of controls as well as the unknown SN samples at 30 min intervals between 0 to 2 h
(Figure 1). BSA was used as a positive control in conjunction with NHS as a means to
correct for NHS interference. As it is seen in Figure 1, BSA (▬) has a much stronger
absorbance (~3  0.14) than NHS (▷; ~2.25  0.26) or gelatin (○; ~0.95  0.38) that
allows BSA to have looser incubation time limits than that of gelatin.

Figure 1: BCA Assay Kinetics. Absorbance rate measurement of bovine serum albumin
(BSA) protein, gelatin with NHS, gelatin alone, NHS alone, and sample SNs. Data was
taken every 30 seconds for 2 h. Test was conducted at 37°C throughout its entirety.
Arrow indicates point of interest at ~20 min where gelatin and NHS responses are equal.
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Additionally, BSA has a much steeper absorbance rate than NHS or gelatin, which
suggests that BSA may be incubated longer for accurate estimations. This is not the case
for gelatin alone and SNs. In fact, the slopes for gelatin alone and SN curves are flatter.
The absorbance of NHS surpassed that of only gelatin (arrow), as well as the SNs’
absorbance, before 30 min indicating a strong interference from NHS. To test this
hypothesis, an additional kinetics study was conducted by varying the concentration (0500 g/ml) of NHS to determine the minimum NHS concentration that would eliminate
the background noise and whose BCA absorbance is lesser than unknown SNs (Figure 2).
Our results suggest that a concentration of 100 μg/ml NHS coincides with the
concentration of NHS within the SNs. The SN absorbance is lower than the NHS
absorbance until approximately 30 min (Figure 2) suggesting that an accurate correction
is dependent on incubation time.

Figure 2: BCA Assay Kinetics of NHS. Data was acquired every 30 s for 2 h and
incubated at 37°C for the entire duration. NHS concentrations range from 100-500 µg/ml.
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To test the effect of incubation time further, the samples were read for absorbance
every minute for 45 min in future experiments. To confirm the impact of NHS
concentration again, as well as determine an appropriate incubation time, gelatin
standards were prepared with 100 μg NHS/ml and absorbance was measured using the
BCA protein assay in addition to the SN samples (Figure 3). The SN samples correlated
similarly with the standards and measured above the blank NHS (100 μg/ml of NHS).
The incubation time was another contributing factor. SN samples maintained a similar
slope to that of the standard prepared at 125 g/ml gelatin up to 30 min after which it
matched with the 250 g/ml gelatin standard curve. We confirmed this concentration as
follows.

Figure 3: BCA Assay Kinetics of Gelatin Standards with Fixed NHS Concentration. Data
was acquired every minute for 45 min and incubated at 37°C for the entire duration.
Black shapes represent gelatin standards mixed with a fixed concentration of NHS (100
µg/ml). Red shapes indicate SN samples after EDC/NHS conjugation. Gelatin
concentration ranges from 0-750 µg/ml.
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3.2 BCA ASSAY CORRECTED WITH GELATIN PRECIPITATION USING
COMPAT-ABLE™ PROTEIN ASSAY
To verify the sensitivity of BCA-based gelatin quantification, gelatin was precipitated
in pellets using the Compat-Able™ Protein Assay. The purpose of the kit is to remove
any interfering substances from the pellet. The SN samples and gelatin standards were
precipitated, dissolved in PBS and BCA working reagent, incubated for 2 h at 37°C, and
measured for absorbance (Figure 4). This resulted in a concentration of 121.7 ± 15.44 and
166.3 ± 27.40 g/ml gelatin in PLGA SN and PLGA-PEG SN, respectively.
Additionally, the mixture of 100 μg/ml NHS, after being treated with the precipitating
reagents, recorded an absorbance similar to that of the PBS blank. Using these results, we
matched the concentration calculated through the precipitation method with the sample
incubation time that estimated a similar concentration. Absorbance data were analyzed to
determine gelatin concentration at each time point from Figure 3. After correcting for
NHS interference, it was found that using an incubation time of 20 ± 2 min, the
concentration of PLGA SN was 119.0 ± 20.44 μg/ml gelatin and the concentration in
PLGA-PEG SN was 168.5 ± 27.51 μg/ml gelatin (Figure 5). By utilizing the NHS
correction in the BCA assay, the conjugation percentage of the SN samples was
calculated at 50.71 ± 10.10% and 31.76 ± 10.41% for PLGA SN and PLGA-PEG SN,
respectively (Table 1). A comparison of the effect of the incubation time on the
calculated conjugation percentage was examined (Figure 6). Adjusting the incubation
time, at 37°C, from 30 to 20 min provided a 23% difference in calculated conjugation
percentage. This correlates to a calculated conjugation percentage of 50.7% and 62.4% at
20 and 30 min, respectively for PLGA SN. The data at 20 min corresponds to the
concentration and conjugation percentage determined using the precipitation assay, which
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indicates why adjusting the incubation time is vital in protein estimation procedures. The
data at 20, 30, and 45 min have relatively large standard deviations because data is the
average of three independent experiments which have widely varying conjugation
percentages due to minor variations in experimental conditions such as pH, particle mass,
or gelatin standard concentration. The error bars at 5 min are relatively small because at
this time the BCA assay has not had sufficient time to saturate the sample with color and
create significant distinctions across different concentrations of protein.
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Figure 4: Precipitation Assay. Gelatin standard curve data derived after precipitating
gelatin protein from PBS solution using Compat-Able Protein Assay Kit. After
precipitation, samples were diluted in sample volume used and vortexed to dissolve
pellet. All samples were incubated for 2 h at 37°C and measured immediately using BCA
assay.
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Figure 5: BCA Assay Incorporating NHS Correction. All standards and samples were
incubated at 37°C for 20 min and followed the standard BCA assay. Data represent blank
corrected absorbance. SN samples were further corrected by subtracting the absorbance
of a 100 μg/ml NHS in PBS mixture.

Table 1: Percent Protein Conjugation in SN Sample after NHS Correction. Concentration
was calculated using a standard curve constructed from absorbance measurements of
blank-corrected gelatin standards. Total mass was determined by multiplying
concentration by SN volume. Total gelatin used in the experiment was 740 μg. All
samples were incubated at 37°C for 20 min and subsequently measured for absorbance at
562 nm using the BCA assay.
Sample

SN Concentration
Precipitated (μg/ml)

SN Concentration
BCA Assay (μg/ml)

Conjugation %

PLGA SN

121.7 ± 15.44

119.0 ± 20.44

50.71 ± 10.10

PLGA-PEG SN

166.3 ± 27.40

168.5 ± 27.51

31.76 ± 10.41
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Figure 6: Effect of Incubation Time on Protein Estimation. Results represent average
calculated conjugation percentage of three experiments after 5, 20, 30, and 45 min of
incubation at 37°C for PLGA (■) and PLGA-PEG (●) SNs. Error bars represent mean ±
s.d.

It is thus important to check how extreme the conjugation percentage is distorted over
varying incubation time. Finally, conjugation percentages were verified using the
precipitation assay.

3.3 DISCUSSION
Conducting the assay on a sample containing NHS proposes several problems [18,
19]. NHS reduces the BCA reagent in the same manner as proteins, but the effect is not
additive [18]. Additionally, NHS interference is dependent on incubation time, pH,
protein concentration, and protein composition due to the nature of the BCA assay [20].
The BCA assay is protein specific in that different proteins will produce different levels
of absorbance [6, 16]. For coupling of gelatin on the surface of poly(lactic-co-glycolic)
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acid (PLGA) microparticles, the standard amine coupling includes a three-step reaction
with EDC/NHS chemistry. Upon application of the BCA protein assay, it was found that
the SN samples reported absorbance measurements much higher than standards of known
concentration (Figure 7a). The undiluted sample measured an absorbance value almost
twice as large as the highest protein standard, however, a 50 times dilution (50x dil.) of
the sample led to an absorbance value within the standards’ range. These results were
used to calculate the conjugation efficiency of the EDC/NHS conjugation reaction (Table
2). Sample concentrations were calculated using a best-fit curve correlation derived from
the standards’ data (Figure 8). The total amount of gelatin used in the experiment was 25
mg, however, the lowest calculated amount of gelatin in the supernatant was 90 mg,
almost four times as high. To ensure that the tested sample was not an outlier, EDC/NHS
reaction was performed without gelatin. The supernatant of the conjugation sample was
collected and absorbance was measured (Figure 7b). This EDC/NHS control (without
gelatin) showed higher absorbance than the standards and SNs. Thus, we hypothesized
that NHS must be interfering with the BCA reaction [18].

Table 2: Percent Protein Conjugation of SN Sample
SN Concentration
Dilution
SN Vol (ml) SN Gelatin (μg) Total Gelatin (μg) Conjugation %
(μg/ml)
1

5001 ± 70.34

18

90030 ± 1266

25,000

-260.1 ± 5.06

2

5736 ± 54.89

18

103200 ± 1976

25,000

-313 ± 7.90

5

9543 ± 102.8

18

171800 ± 9253

25,000

-587 ± 37.01

10

16230 ± 105.1

18

292100 ± 18910

25,000

-1068 ± 75.66

50

61630 ± 41.77

18

1109000 ± 37600

25,000

-4337 ± 150.4
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Figure 7: Initial BCA Assay Results. (A) BCA Assay results with gelatin standards (02000 µg/ml) and supernatant samples. All samples were incubated at 37°C for 2 h. SN =
undiluted supernatant sample. 50x Dil = SN diluted at a 50:1 PBS:SN ratio. (B) BCA
Assay results with standards and samples incubated at 37°C for 30 min. Control consists
of a “blank” EDC/NHS conjugation reaction that contained no gelatin protein or PLGA
particles. SN = undiluted supernatant sample.
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Measurements of conjugation samples following the standard procedure like the BCA
assay are challenging. A plethora of interferences can lead to an erroneous composition
of the sample supernatant. If one or several of the interfering factors happen(s) to have an
impact on measurement accuracy, this biasing effect(s) evolve gradually without any
indication in the signal-over-time-curve, leading to significant errors [21, 22]. To detect
such errors, thorough method qualification over time must be followed to conclude the
total protein determination in bioconjugation engineering. There is thus a substantial need
for refined analytical protocols that allow for taking such factors into account, yet without
increasing operator workload beyond a reasonable extent. Against this backdrop, the aim
of this study was to evaluate and illustrate the impact of NHS on gelatin quantification
via the BCA assay, as well elucidate a rapid and generally applicable method to
compensate for the biasing effects.

Figure 8: Gelatin standard curve using BCA assay (37C/ 2h incubation).
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The incubation time to accurately estimate gelatin concentration in SN samples varied
significantly between PLGA SN and PLGA-PEG SN after initial analysis. However,
upon application of the suggested modification to the BCA assay protocol, the PLGAPEG SN estimation was satisfactory after 20 min of incubation time. The incubation time
varied for PLGA-PEG SN samples initially due to PLGA-PEG particles being aspirated
during washing and being present in the PLGA-PEG SN. These particles are saturated
with NHS esters that are bound to carboxylic acid groups on either the gelatin protein or
particles themselves [23]. This NHS ester hydrolyzes within minutes to several hours
depending on the pH of the solution [24]. When the ester bond hydrolyzes, the NHS
concentration in the SN sample increases which causes a higher absorbance measurement
to be read leading to lower conjugation percentages and a skewed determination of
necessary incubation time. Preventing particle aspiration into the SN is of paramount
importance to accurate protein concentration estimation.
The BCA Assay gives an overestimated value when a sample contains NHS. The
sample emits a much darker purple color than any of the standards, even when it is
known that the sample has a lower concentration of protein. Quantitatively, the measured
absorbance of the samples containing NHS is larger than any of the standards. When
calculating the concentration of the sample using the standard curve correlation, the
sample protein concentration is estimated far past the range of the standard curve. When
calculating total protein content in the sample (multiplying calculated concentration by
total supernatant volume) the result is significantly higher than the original starting
amount. The inaccuracy in the results is due to the interactions between the protein, NHS,
and the BCA assay reagents. Multiple mechanisms are believed to induce the strong
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interference of NHS with the BCA assay. One of the proposed mechanisms is that NHS
directly reduces the cupric ion (Cu2+) present in the BCA working reagent into the
cuprous ion (Cu+) which participates in the colorimetric chelation reaction [25]. Another
proposed mechanism is an esterification reaction between NHS and free protein in the
sample, which is part of the protein conjugation reaction [23]. This esterification reaction
is thought to prevent free protein in the sample from reducing the Cu2+ ion to the Cu+ ion
and subsequently block the colorimetric reaction. This effect is more pronounced at
higher protein concentrations (Figure 4). For this reason, the NHS interference in the
assay is not additive and is dependent on protein concentration. The reaction kinetics in
response to the BCA working reagent of NHS and gelatin differ (Figure 2), which creates
the issue with appropriate incubation time. Additionally, the ability for gelatin to induce a
color response to the BCA reagent is significantly low which creates even more difficulty
in correcting for NHS interference (Figure 2). This weak response to the BCA reagent is
due to the low content of cysteine, cystine, tryptophan, and tyrosine amino acids in
gelatin, which are known to reduce the Cu2+ ion [26-28]. Since NHS interference
increases with time and varies depending on protein concentration, a unique method must
be employed to correct samples being tested after an EDC/NHS reaction. The method
proposed for correcting NHS interference is to perform the BCA Assay using standards
composing of the protein being investigated as well as creating an NHS blank. Following
20 min incubation time and absorbance measurements at 562 nm, the NHS absorbance
must be subtracted from all unknowns before calculating concentrations using the
standard curve.
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There are other methods such as a precipitation assay being a useful method for
removing interfering substances. However, the precipitation assay has the potential to
produce abnormal results and requires several iterations to realize a meaningful result.
Additionally, with low concentrations, the protein pellet formed is so small that it can
easily be lost during the precipitation procedure. Additionally, this assay adds a
significant amount of work to the researcher because all standards and experimental
samples must be precipitated and then analyzed using the quantitative assay in question.
The Bradford method is another example. However, there are other
proteins/substances that do not respond well to the Bradford method and are better
analyzed using the BCA assay. Gelatin is one of the proteins that does not have a strong
response to the Bradford method, or rather the Coomassie reagent, unless significant
alterations to the assay’s protocol are made.
This report is the first time an analysis has been conducted on the response of
different concentrations of NHS to the BCA assay and the effect NHS has on the BCA
assay. This is important because it shows that certain substances can interact with the
assay in such a way that the interference can go undetected. This is because when a
sample subject to the BCA assay consists of both protein and NHS, there are competing
reactions between NHS and the protein to reduce the cupric ion to the cuprous ion. This
competing nature results in a masking of the actual nature of the protein since NHS will
inhibit the reduction of the cupric ion by binding to the protein in an esterification
reaction, but also reducing the cupric ion to cuprous. This phenomenon has been
reported, however, accurate and detailed corrections for this phenomenon have not been
thoroughly investigated until now.
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4. CONCLUSIONS

The BCA assay is subjected to immense interference by NHS due to Cu2+ reduction
as well as esterification with free protein in the sample such that even a concentration of
100 μg/ml induces large deviations. It is important to note that when conducting the BCA
assay after a conjugation reaction involving NHS, NHS concentration in the sample is
less than that originally used in the reaction. Using an NHS blank in tandem with the
BCA assay standards provides a suitable correction in protein concentration estimation.
Additionally, adjusting incubation time of the sample to approximately 20 min at 37°C
and subtracting the NHS blank provides an accurate estimation of protein in the sample.
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SECTION
2. CONCLUSIONS

In summary, these investigations have achieved the following outcomes: (1) synthesis
of biodegradable PLGA microparticles more than 100 µm in size, (2) successful
attachment of HUVEC cells to the surface of these particles, and (3) determining a
plausible correction for NHS interference in the BCA assay for protein quantification.
These achievements are important in the field of tissue, biological, and chemical
engineering, as well as in chemistry. They offer new methodologies for the formulation
of bioactive, polymeric materials, as well as provide a new approach to accurately
determining the extent of surface modification of these materials. These findings will
help future researchers to develop improved models in cellular transport for augmenting
tissue response as well as reliable assessment of the characterization of bioactive
scaffolds and other materials.
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3. FUTURE WORK

In the future, this research can be extrapolated for in vivo analysis of cellular delivery
via microparticle transports. Currently, this research will be extended to an ex vivo model
consisting of skin tissue samples obtained from The Dermatology Center in Rolla, MO
under the supervision of Dr. William V Stoecker in collaboration with the Phelps County
Regional Medical Center. Microparticles will be applied to these skin tissue samples and
investigated for wound repair augmentation compared to control wound recovery
processes. Further, mice or rat models will be used to assess the in vivo potential of these
microparticles transports. Additionally, other tissues, such as cardiac, bone, or cartilage,
could be assessed for repair augmentation using this microparticle system.
Research is currently in progress on polymeric coatings to protect and incorporate
cell-covered microparticles for deployment in medical centers and rural or unpopulated
areas. Development of a protective polymeric sheath will enable these devices to be
transported easily and safely as well as used immediately under any crisis. This will be
especially useful in emergency medical situations – emergency medical technicians
(EMTs) for example – or in burn victims right at the scene of an incident. Producing
technologies of this kind is important, especially in burn victims, as fibrotic scarring and
irreparable damage can happen quickly.
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APPENDIX

Control

PLGA

PG

P2

P2G

8h

Figure A.1: HUVECs on microparticles at 8h. HUVEC cells have noticeably started
to stop associating with particles and not attach as well across all formulations. However,
cells still maintain viability.

4h

8h

24h

72h

Figure A.2: PLGA-PLL (P2) particles seeded with MDA-MB-231 breast cancer cells.
At 4, 8, and 24 hours, cells are noticeably attached to particles and viable, indicated by
green fluorescence. At 72h, many cells attached to particles do not fluoresce indicating
that these cells have lost viability and are undergoing apoptosis.
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Figure A.3: Overview of microparticle synthesis setup with flow-focusing device.
Two syringes are connected to tygon tubing through a needle, which is threaded through
a glass pasteur pipet. One 10 ml syringe and one 5 ml syringe is used, the former
containing a 1% PVA carrier stream and the latter containing the organic stream
comprised of PLGA and ethyl acetate. The organic stream tubing is threaded to the neck
of the pipet to facilitate formation of droplets whereas the carrier stream is left at the
mouth of the pipet.
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